ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
BLyS/BAFF Inhibitor (Anti-B-Lymphocyte Stimulator) Pregnancy: Avoid — IgG crosses placenta; potential B-cell depletion in neonate; effective contraception required during and for 4 months after treatment

Belimumab (Cutaneous Lupus)

Brand names: Benlysta

Adult dose

Dose: IV: 10 mg/kg every 2 weeks ×3, then every 4 weeks; SC: 200 mg once weekly
Route: IV infusion or SC injection
Frequency: Monthly IV (after loading) or weekly SC
Max: 10 mg/kg per IV dose
Active SLE with skin involvement — cutaneous lupus (SCLE, CCLE, discoid lupus); continue standard treatment (hydroxychloroquine, steroids); SC self-administration available after training

Paediatric dose

Dose: 10 mg/kg IV every 2 weeks ×3 then every 4 weeks mg/kg
Route: Intravenous
Frequency: Every 4 weeks (after loading)
Max: Per weight calculation
Licensed for paediatric SLE ≥5 years (IV route only)

Dose adjustments

Renal

No dose adjustment required; monitoring advised in severe renal impairment

Hepatic

No dose adjustment required

Paediatric weight-based calculator

Licensed for paediatric SLE ≥5 years (IV route only)

Clinical pearls

  • BLISS-52 and BLISS-76 (Navarra et al. NEJM 2011 / Furie et al. ARTHRITIS RHEUM 2011): belimumab + standard care significantly improved SRI-4 response vs placebo; benefit particularly pronounced in high-disease-activity patients and those with anti-dsDNA positive/low complement
  • BLyS (B-lymphocyte stimulator)/BAFF promotes B-cell survival and differentiation — in SLE, excessive BLyS production drives autoreactive B-cell survival; belimumab reduces circulating plasmablasts and pathogenic autoantibodies (anti-dsDNA)
  • Cutaneous lupus response: post-hoc analyses show improvement in cutaneous activity scores (CLASI); beneficial in SCLE and discoid lupus overlapping with SLE; for purely cutaneous lupus without systemic disease, evidence is less robust — specialist rheumatology/dermatology decision
  • MHRA neuropsychiatric warning: depression, suicidal ideation, and self-harm reported — screen at baseline; monitor mood; contraindicated if actively suicidal; share decision-making with patient regarding risk
  • SC formulation (Benlysta 200 mg pen): allows home administration after 3 supervised doses — improves QoL vs monthly IV infusions; clinical response equivalent; suitable for stable patients with good injection technique

Contraindications

  • Active CNS lupus (not adequately studied)
  • Severe active lupus nephritis (limited data)
  • Live vaccines — contraindicated
  • Known hypersensitivity to belimumab

Side effects

  • Infections (upper respiratory, urinary tract)
  • Nausea
  • Diarrhoea
  • Infusion/injection site reactions
  • Depression and suicidal ideation (MHRA warning)
  • Serious infections including PML (rare)

Interactions

  • Live vaccines — avoid during and for up to 30 days before treatment
  • Other biologics — additive immunosuppression; avoid combination

Monitoring

  • SLE disease activity (SLEDAI)
  • Cutaneous lupus activity (CLASI)
  • Anti-dsDNA and complement (C3/C4)
  • FBC and immunoglobulins
  • Neuropsychiatric symptoms
  • Infection surveillance

Reference: BNFc; BNF 90; BLISS-76 trial (Furie et al. 2011); BLISS-52 trial (Navarra et al. NEJM 2011); NICE TA397; MHRA SPC Benlysta; BSR/BHPR Lupus Guidelines (2022). Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways